The size of the Asia Pacific Parkinson’s Disease Treatment Market was worth USD 1.4 billion in 2019 and estimated to be growing at a CAGR of 5.88%, to reach USD 1.86 billion by 2024.
Europe Parkinson's Disease Treatment Market is growing at a high pace as the incidence of Parkinson's disease is increasing in developed countries. The value of Europe Parkinson's disease treatment market in 2019 was $ 2.94 billion, and it is likely to register a CAGR above 11% in the coming years. Europe Parkinson's Disease Treatment market propels with a growing public understanding of this disease, the multiplying elderly population, the prospect of launching pipeline drugs and new products, and relatively high growth in the therapeutic market.
Parkinson's disease is termed as a progressive neurodegenerative disorder that affects dopaminergic neurons in the brain. Parkinson's disease mainly causes tremors, muscle stiffness, abnormal movement, walking, and balance problems. Secondary symptoms of this ailment include anxiety, depression, and dementia. The exact etiology of Parkinson's disease is unknown and mainly affects older people over the age of 50, but men suffer half of the women's illnesses. According to estimates by the United States Parkinson Foundation, the disease affects about 70 to 10 million people worldwide, and about 60,000 Americans are diagnosed with the disease each year. In developed regions like Europe, the high prevalence and risk of this disease are driving the growth of Parkinson's disease treatment market.
However, it is expected that the patent expiry of crucial drugs and side effects related to therapeutic medicines will limit the growth of Europe Parkinson's disease treatment market over the forecast period.
The government and non-profit organizations' understanding of Parkinson's disease and higher clinical research and development budgets are expected to drive the growth of Parkinson's treatment market over the forecast period. Promising product channels represent potential business development opportunities over the projection period. In the United States, in phase III clinical study, about ten drugs are used to treat different symptoms of Parkinson's disease.
The availability of alternative therapies limits the market with advanced technology.
This research report is segmented and sub-segmented into the following categories:
Regionally, Europe is supposed to gain the largest share of the global Parkinson's disease treatment market, followed by North America, and its market share is also considerable. Understanding of treatment, increased expenditure on research and development, favorable drug reimbursement regulations and policies, high incidence of Parkinson's disease, the rapid increase in the elderly population, and potential medical pipeline products may account for a significant share of the Europe Parkinson's disease treatment market. The regional market is foreseen to grow at a reasonable rate. The most critical market share in the European Parkinson's disease treatment market may be occupied by nations like the UK, Germany, France, etc., mainly due to a large number of patients with Parkinson's disease in these countries.
Leading companies dominating the European Parkinson’s Disease Treatment Market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Dopamine Receptor Antagonists
5.1.1.1 Pramipexole
5.1.1.2 Ropinirole
5.1.1.3 Apomorphine
5.1.1.4 Rotigotine
5.1.2 Mono Amine Oxidase Inhibitors
5.1.2.1 Selegiline
5.1.2.2 Rasagiline
5.1.3 Carbidopa
5.1.4 Anticholinergics
5.1.5 Other Drug Classes
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, By Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Distribution Channel
5.2.1 Retailer Pharmacies
5.2.2 Hospital Pharmacies
5.2.3 Online Pharmacies
5.2.4 Y-o-Y Growth Analysis, By Distribution Channel
5.2.5 Market Attractiveness Analysis, By Distribution Channel
5.2.6 Market Share Analysis, By Distribution Channel
5.3 Patient Care Setting
5.3.1 Clinics
5.3.2 Hospitals
5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting
5.3.4 Market Attractiveness Analysis, By Patient Care Setting
5.3.5 Market Share Analysis, By Patient Care Setting
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Drug Class
6.1.3.2 By Distribution Channel
6.1.3.3 By Patient Care Setting
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Drug Class
6.1.4.2 By Distribution Channel
6.1.4.3 By Patient Care Setting
6.1.5 Market Share Analysis
6.1.5.1 By Drug Class
6.1.5.2 By Distribution Channel
6.1.5.3 By Patient Care Setting
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Teva
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 GSK
8.4 AbbVie
8.5 Merck
8.6 Boehringer Ingelheim
8.7 Impax Laboratories
8.8 Lundbeck
8.9 Sun Pharma
8.10 Wockhardt
8.11 UCB
8.12 Valeant Pharmaceuticals
8.13 Acadia
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
